"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA grants accelerated approval to enfortumab vedotin-ejfv (Padcev) for metastatic urothelial cancer

FDA grants accelerated approval to enfortumab vedotin-ejfv (Padcev) for metastatic urothelial cancer

19 Dec 2019 1:49 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev; Astellas) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software